stockrow
Friday 6 November 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
91.42
4.24
+4.86%
Follow SOLV
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 6 | 5 | 5 |
+8 more TTM periods Free account |
| 3.19% | 33.96% | 34.79% | 38.86% | ||
| 1.11% | 9.78% | 10.01% | 10.82% | ||
ROIC |
0.00% | 13.40% | 13.60% | 14.81% | |
Return on Tangible Assets |
133.33% | 87.28% | 80.45% | 75.94% | |
Average Days of Receivables |
62.20 | 62.90 | 52.13 | 51.91 | |
Free Cash Flow per Share |
0.00 | (0.68) | (1.17) | (0.06) | |
Free Cash Flow |
0.00 | (118.00) | (203.00) | (10.00) | |
Capital Expenditures |
(310.00) | (327.00) | (354.00) | (379.00) | |
| Other line items | |||||
Cash ROIC |
0.00% | (1.12%) | (1.88%) | (0.09%) | |
Accounts Receivable Turnover |
6.36 | 6.19 | 7.21 | 6.90 | |
Accounts Payable Turnover |
0.00 | 5.60 | 5.88 | 5.94 | |
Inventory Turnover |
0.00 | 3.76 | 3.92 | 3.81 | |
Average Days of Payables |
0.00 | 67.94 | 66.63 | 64.73 | |
Days of Inventory on Hand |
0.00 | 100.80 | 103.81 | 100.44 | |
Tax Rate |
(0.08) | (0.15) | (0.15) | (0.09) | |
Research and Development Expense of Revenue |
8.84% | 8.71% | 8.90% | 8.88% | |
Selling, General and Administrative Expense of Revenue |
40.74% | 39.63% | 37.98% | 37.00% | |
Share Based Compensation of Revenue |
2.06% | 2.01% | 1.97% | 1.93% | |
Interest Coverage |
0.00 | 7.80 | 6.91 | 6.29 | |
Operating CF/Net income |
1.99 | 0.15 | 0.11 | 0.24 | |
Depreciation/Fixed assets |
0.00 | 0.32 | 0.32 | 0.37 | |
Capex/Depreciation |
(0.59) | (0.65) | (0.72) | (0.78) | |
Revenue per Share |
47.79 | 48.12 | 47.43 | 47.82 | |
Operating CF per Share |
1.82 | 1.21 | 0.87 | 2.12 | |
Capex per Share |
(1.81) | (1.89) | (2.03) | (2.18) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026